相关实验视频

Updated: May 30, 2025

Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice

Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice

Published on: June 2, 2022

阿斯特拉加索酸IV通过调节肠道微生物群和肠道微生物群的代谢减轻GDM

Fengge Wang¹, Yongning Zhu¹, Hua Shu¹

¹Department of Obstetrics, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China.

Frontiers in pharmacology

|January 31, 2025

概括

甲酸IV (AS IV) 通过改善葡萄糖控制和生殖结果,有效地缓解了大鼠的妊娠糖尿病 (GDM). 这种天然化合物调节肠道微生物群和代谢物概况,为GDM提供了有前途的干预措施.

科学领域:

内分泌学在内分泌学.
微生物学微生物学
药理学药理学是指药理学的学科.

背景情况:

孕期糖尿病 (GDM) 是一种严重的妊娠并发症.
阿斯特拉加索酸IV (AS IV) 源自Astragalus membranaceus,已经显示出抗糖尿病作用.
AS IV对GDM的影响,特别是其涉及肠道微生物群的机制,仍然不清楚.

研究的目的:

在大鼠模型中研究AS IV在改善GDM方面的疗效.
为了确定AS IV的抗GDM特性是否由肠道微生物群和代谢物调节介导.

主要方法:

在Sprague-Dawley大鼠中使用链毒素诱导GDM.
在怀孕前和怀孕期间给孕大鼠注射了AS IV.
评估了GDM的关键指标,生殖结果,肠道微生物群 (16S rRNA测序) 和代谢概况 (LC-MS).

主要成果:

在GDM大鼠中,AS IV治疗显著降低了空腹血糖,胰岛素水平和胰岛素抵抗.
AS IV改善了生殖结果,降低了形率并增加了胎儿体重.
AS IV调节了肠道微生物群的组成,减少了有害细菌 (例如,Blautia) 和增加了有益的细菌 (例如,Methanobrevibacter).
AS IV增加了特定代谢物 (例如N-乙-l-氨酸,石灰酸) 并确定了肠道细菌和代谢物之间的关联.

结论:

在老鼠中,AS IV显示了对GDM的显著治疗潜力.
AS IV通过调节肠道微生物群和代谢组概况来发挥其抗GDM作用.
AS IV代表了一种可行的营养干预策略,用于管理GDM.

关键词:

阿斯特拉加洛西德IV 孕期糖尿病孕期糖尿病我们的肠道微生物群.与肠道微生物群相关的代谢物.代谢代谢代谢代谢

更多相关视频

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants

Using a Murine Model of Psychosocial Stress in Pregnancy as a Translationally Relevant Paradigm for Psychiatric Disorders in Mothers and Infants

Published on: June 13, 2021

Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring

Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring

Published on: May 17, 2024

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Pathophysiology of Diabetes

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...